Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + anlotinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
serplulimab + anlotinib + nab-paclitaxel is a combination regimen consisting of the anti-programmed cell death protein 1 (PD-1) monoclonal antibody serplulimab, the multitarget tyrosine kinase inhibitor (TKI) anlotinib, and the microtubule inhibitor nab-paclitaxel (nanoparticle albumin-bound paclitaxel). This triplet combination is being evaluated as a second-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed on prior first-line immunochemotherapy. Serplulimab enhances T-cell-mediated antitumor immune responses by blocking the PD-1/PD-L1 pathway, while anlotinib inhibits tumor angiogenesis and growth by targeting vascular endothelial growth factor receptors (VEGFR1/2/3), fibroblast growth factor receptors (FGFR1/2/3/4), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit. Nab-paclitaxel delivers cytotoxic chemotherapy by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis. Together, these agents act synergistically to overcome immune resistance, inhibit angiogenesis, and promote tumor cell death.
- Other names
- serplulimab + anlotinib + albumin-bound paclitaxelserplulimab + anlotinib + nanoparticle albumin-bound paclitaxelserplulimab, anlotinib and nab-paclitaxel
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on serplulimab + anlotinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + anlotinib + nab-paclitaxel.